Keywords: amylin, 1st, qtr, suffers, low, byetta, sales
Amylin's 1st qtr suffers from low Byetta sales
Article | 05 May 2008
The USA's Amylin Pharmaceuticals first-quarter 2008 net loss totaled $68.8 million, or $0.51 per share, an improvement on the $49.4 million, or $0.38 per share, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
